Elicio Therapeutics (ELTX) vs eXoZymes (EXOZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
eXoZymes (EXOZ) has outperformed Elicio Therapeutics (ELTX) over the past year, losing 59.0% versus a loss of 82.8%. eXoZymes is the larger company by market cap ($49.0 million vs $47.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELTX | EXOZ |
|---|---|---|
| Share price | $1.81 | $5.27 |
| Market cap | $47.57M | $49.04M |
| 1-day change | -2.16% | -4.87% |
| YTD return | -77.26% | -49.17% |
| 1-year return | -82.79% | -58.96% |
| 5-year return | -97.92% | — |
| EPS (TTM) | $-2.16 | $-1.19 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.00 | $18.40 |
| 52-week low | $1.71 | $4.35 |
| Distance from 52-week high | -88.69% | -71.36% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +655.25% | — |
| Average volume | 352.93K | 6.80K |
| Shares outstanding | 26.28M | 9.30M |
| Employees | 33 | 32 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EXOZ has outperformed ELTX by 23.8 percentage points over the past year.
About Elicio Therapeutics
ELTX stock →Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations.
Healthcare · Biotechnology · 33 employees
About eXoZymes
EXOZ stock →eXoZymes, Inc. operates as a development stage biotechnology company.
Healthcare · Biotechnology · 32 employees
ELTX vs EXOZ FAQ
Which is bigger, Elicio Therapeutics or eXoZymes?
eXoZymes (EXOZ) is larger, with a market capitalization of $49.04M compared with $47.57M for Elicio Therapeutics (ELTX).
Which stock has performed better over the past year, ELTX or EXOZ?
EXOZ returned -58.96% over the past 12 months, compared with -82.79% for ELTX (price return, excluding dividends). Past performance does not predict future results.
Are Elicio Therapeutics and eXoZymes in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.